These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 36122506)

  • 21. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer.
    Akbarzadeh M; Mihanfar A; Akbarzadeh S; Yousefi B; Majidinia M
    Life Sci; 2021 Nov; 285():119984. PubMed ID: 34592229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy.
    Celtikci B
    Adv Exp Med Biol; 2021; 1275():357-382. PubMed ID: 33539023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inorganic polyphosphate promotes cyclin D1 synthesis through activation of mTOR/Wnt/β-catenin signaling in endothelial cells.
    Hassanian SM; Ardeshirylajimi A; Dinarvand P; Rezaie AR
    J Thromb Haemost; 2016 Nov; 14(11):2261-2273. PubMed ID: 27546592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
    Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
    Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways.
    Yassin NYS; AbouZid SF; El-Kalaawy AM; Ali TM; Almehmadi MM; Ahmed OM
    Biomed Pharmacother; 2022 Jan; 145():112409. PubMed ID: 34781148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K/AKT/GSK-3β/mTOR and Wnt/β-catenin pathways;
    Abdel-Rafei MK; Thabet NM; Rashed LA; Moustafa EM
    J Cancer Res Ther; 2021; 17(6):1404-1418. PubMed ID: 34916371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells.
    Lau MT; So WK; Leung PC
    PLoS One; 2013; 8(3):e59083. PubMed ID: 23554977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteinizing hormone stimulates mammalian target of rapamycin signaling in bovine luteal cells via pathways independent of AKT and mitogen-activated protein kinase: modulation of glycogen synthase kinase 3 and AMP-activated protein kinase.
    Hou X; Arvisais EW; Davis JS
    Endocrinology; 2010 Jun; 151(6):2846-57. PubMed ID: 20351317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Huang-Lian-Jie-Du-Decotion induced protective autophagy against the injury of cerebral ischemia/reperfusion via MAPK-mTOR signaling pathway.
    Wang PR; Wang JS; Zhang C; Song XF; Tian N; Kong LY
    J Ethnopharmacol; 2013 Aug; 149(1):270-80. PubMed ID: 23811213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.
    Baryawno N; Sveinbjörnsson B; Eksborg S; Chen CS; Kogner P; Johnsen JI
    Cancer Res; 2010 Jan; 70(1):266-76. PubMed ID: 20028853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
    Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
    Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retracted: Girinimbine Inhibits the Proliferation of Human Ovarian Cancer Cells In Vitro via the Phosphatidylinositol-3-Kinase (PI3K)/Akt and the Mammalian Target of Rapamycin (mTOR) and Wnt/β-Catenin Signaling Pathways.
    Xin Q; Muer A
    Med Sci Monit; 2021 Mar; 27():e931225. PubMed ID: 33704262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
    Zhao M; Ramaswamy B
    World J Clin Oncol; 2014 Aug; 5(3):248-62. PubMed ID: 25114842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
    Liu C; Pei J; Mu X; Yu B; Gong T; Liang W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unveiling the connection: Long-chain non-coding RNAs and critical signaling pathways in breast cancer.
    Thapa R; Afzal O; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Altamimi ASA; Subramaniyan V; Thangavelu L; Singh SK; Dua K
    Pathol Res Pract; 2023 Sep; 249():154736. PubMed ID: 37579591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.